Support our Linked Clinical Trials Programme

The LCT programme is spearheaded by The Cure Parkinson's Trust to prioritise and fast-track drugs, currently used to treat other conditions, with the potential to slow, stop, or reverse Parkinson's. Read more

GLP-1 Agonists - donate to fund this research

Liraglutide, Lixisenatide, Exenatide and Bydureon belong to a group of safe and well-tolerated drugs called GLP-1 agonists. They are used to treat type 2 diabetes and in recent years there has been research based evidence to suggest that they show great promise as a new treatment for Parkinson's. Read more